Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
19/03/2018Appendix 3B-PlacementDownload
19/03/2018Cleansing NoticeDownload
16/03/2018Race increases placement to $3.69mDownload
12/03/2018Race completes over-subscribed $3.159 million placementDownload
07/03/2018Trading HaltDownload
27/02/2018Appendix 3BDownload
27/02/2018Section 708A NoticeDownload
21/02/2018Second Bisantrene Patent Allowed in USDownload
20/02/2018Appendix 4D & Half-Year Financial StatementsDownload
09/02/2018Appendix 3BDownload
1  2  3  4  5  6  7  8  9  10  11  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier